The popularity of Sildenafil initially drove a period of growth for pharma, but recent shifts present a uncertain picture for investors. Off-patent competitors are reducing profits, and persistent litigation add https://oisiyeid051998.ourcodeblog.com/41576589/viagra-and-pharma-a-volatile-play